Scott Wasserman, M.D.

Bio:

Scott Wasserman, MD, serves as Chief Medical Officer of Kailera Therapeutics. He has extensive experience in clinical development, including global development strategy, clinical trial design and execution, and global regulatory interactions. Most recently, he was a Venture Partner at Frazier Life Sciences, where he focused on company creation. Previously, he served as CEO and co-founder of Latigo Biotherapeutics, a venture-backed biotechnology company developing first- and best-in-class non-opioid pain medicines.

Earlier in his career, Wasserman served as Vice President, Global Development Therapeutic Area Head for Bone, Cardiovascular, Metabolic, and Neuroscience at Amgen. As Amgen’s first cardiologist, he built the company’s cardiovascular and metabolic portfolios and teams. He led the development and global approvals of Repatha^® to reduce LDL cholesterol and prevent heart attacks and strokes. He also played a key role in the development and FDA approval of Evenity^® for the treatment of osteoporosis in postmenopausal women at high risk for fracture and led the team responsible for the FDA approval of Aimovig^® for migraine prevention. In addition, he oversaw therapeutic development programs in heart failure, anemia, obesity, and Alzheimer’s disease.

Before joining the biopharmaceutical industry, Wasserman was a faculty member in Stanford University’s Division of Cardiovascular Medicine, where he conducted NIH-sponsored research on endothelial gene expression. He also practiced as a non-interventional cardiologist at the Veterans Affairs hospital in Palo Alto, California.

Wasserman earned a BS, magna cum laude, from Haverford College and an MD, magna cum laude, from Harvard Medical School. He completed postgraduate training in internal medicine and cardiovascular medicine at Stanford University, as well as postdoctoral cardiovascular research at COR Therapeutics, Millennium Pharmaceuticals, and Stanford. He serves on the board of Inhibikase Therapeutics (Nasdaq: IKT), a clinical-stage company focused on pulmonary arterial hypertension.